

Study with the several resources on Docsity
Earn points by helping other students or get them with a premium plan
Prepare for your exams
Study with the several resources on Docsity
Earn points to download
Earn points by helping other students or get them with a premium plan
Community
Ask the community for help and clear up your study doubts
Discover the best universities in your country according to Docsity users
Free resources
Download our free guides on studying techniques, anxiety management strategies, and thesis advice from Docsity tutors
Information for patients about cefazolin, an antibiotic used to treat bacterial infections. It covers what cefazolin is, its uses, warnings, precautions, dosage instructions, and administration methods. It also mentions potential interactions with other medicines and adverse effects.
What you will learn
Typology: Slides
1 / 2
This page cannot be seen from the preview
Don't miss anything!
Package leaflet: Information for the patient
Cefazolin 1 g Powder for solution for injection/infusion Cefazolin 2 g Powder for solution for injection/infusion Cefazolin (as Cefazolin sodium)
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
The name of your medicine is Cefazolin 1 g Powder for solution for injection/infusion and Cefazolin 2 g Powder for solution for injection/infusion. In the rest of this leaflet the name of the medicine shall be Cefazolin.
What is in this leaflet
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy Cefazolin crosses the placenta and can affect the unborn child. Therefore, if you are pregnant, your doctor should only give you cefazolin if clearly necessary and after careful consideration of benefits and risks. Breast-feeding Cefazolin passes in small amounts into breast milk. Therefore, breastfeeding should be discontinued during treatment with Cefazolin. Driving and using machines Cefazolin has no or negligible influence on the ability to drive and use machines. Cefazolin contains sodium 1 g vial: This medicine contains 50.6 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 2.5% of the recommended maximum daily dietary intake of sodium for an adult. 2 g vial: This medicine contains 101.2 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 5% of the recommended maximum daily dietary intake of sodium for an adult.
3. How Cefazolin is given Administration: Cefazolin is always administered by healthcare personnel. It will be given as an injection or infusion (into a vein) after being dissolved, or into a muscle (intramuscularly) as a deep IM injection. Your doctor will inform you about the necessary duration and frequency of administration of Cefazolin. The recommended doses are: Adult patients with normal kidney function
200 x 650 mm ARIAL 9 pt
Preparation and handling Preparation of the solution For each route of administration see the table for addition volumes and solution concentrations, which may be useful when fractional doses are required. Guidelines for adult dosage Intramuscular injection Cefazolin 1 g: Reconstitute Cefazolin with one of the following compatible diluents according to the dilution table that follows:
Reconstitution table for intramuscular injection
Content per vial
Amount of diluent to be added
Approximate concentration
1 g 2.5 mL 330 mg / mL
For the amount of diluent to be added for paediatric population please refer to section Guidelines for paediatric dosage. Use of lidocaine: In case a lidocaine solution is used as a solvent, cefazolin solutions must only be used for intramuscular injection. Contraindications to lidocaine, warnings and other relevant information as detailed in the Summary of Product Characteristics of lidocaine must be considered before use. The lidocaine solution should never be administered intravenously. IM injection with lidocaine as solvent is indicated for children over 30 months old. Cefazolin 2 g: Should not be used for intramuscular administration. Intravenous injection Reconstitute Cefazolin with of one of the following compatible diluents according to the dilution table that follows:
Reconstitution table for intravenous injection
Content per vial
Minimum amount of diluent to be added
Approximate concentration
1 g 4 mL 220 mg / mL
Cefazolin is to be injected slowly over three to five minutes. In no case should the solution be injected in less than 3 minutes. This should be done directly into the vein or into the tube from which the patient receives intravenous solution. Single doses exceeding 1 g should be given as intravenous infusion over 30 to 60 minutes. Guidelines for paediatric dosage: 1 g vial: The content of 1 vial (1000 mg cefazolin) is dissolved in 4 mL of a compatible solvent (i.e. concentration approx. 220 mg / mL). The respective volume of this solution to be used is indicated in table 1 in addition to the dose in mg. 2 g vial: The content of 1 vial (2000 mg cefazolin) is dissolved in 10 ml of a compatible solvent (i.e. concentration approx. 180 mg / mL). The respective volume of this solution to be used is indicated in table 2 in addition to the dose in mg. For the amount of diluent to be added for paediatric population please refer to section Guidelines for paediatric dosage. For volumes inferior of 1 mL, please use a 0.5 mL syringe for better accuracy of dosing. Intravenous infusion Cefazolin should first be reconstituted with one of the diluents detailed as compatible for intravenous injection. Further dilution should take place with one of the following compatible diluents according to the dilution table that follows:
Dilution table for intravenous infusion
Content per vial
Reconstitution Dilution
Approximate concentration
Minimum amount of diluent to be added
Amount of diluent to be added
1 g 4 mL 50 mL - 100 mL
20 mg / mL - 10 mg / mL
2 g 8 mL 50 mL - 100 mL
40 mg / mL - 20 mg / mL
For Cefazolin 2 g, if smaller doses are needed, it is recommended to use half of the reconstituted solution (about 4 mL with 1 g cefazolin; i.e. half of the vial content) and to add a compatible diluent to a final volume of 100 mL (resulting
concentration about 10 mg / mL). The required amount of this diluted solution can then be administered to the patient over the prescribed time.Cefazolin solutions containing lidocaine should never be administered intravenously. As for all parenteral medicinal products, inspect the reconstituted solution visually for particulate matter and discoloration prior to administration. The solution should only be used if the solution is clear and practically free from particles. The reconstituted product is for single use only. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Incompatibilities Cefazolin is incompatible with amikacin disulfate, amobarbital- sodium, ascorbic acid, bleomycin sulphate, calcium gluceptate, calcium gluconate, cimetidine hydrochloride, colistin methat- sodium, erythromycin gluceptate, kanamycin sulphate, oxytetracyclin hydrochloride, pentobarbital-sodium, polymyxin- B-sulphate and tetracycline hydrochloride. Posology and method of administration The dosage as well as the method of administration are dependent on the location and severity of the infection and on the clinical and bacteriological progress. Local therapeutic guidance should be taken into consideration. Adults and adolescents (above 12 years of age and ≥ 40 kg bodyweight)
Cefazolin maintenance therapy in patients with renal impairment
Creatinine clearance (ml/min)
Serum creatinine (mg/dl)
Dosage
Normal dose and normal dosage interval
35 - 54 1.6 - 3.0 Normal dose, every 8 hours
Half of the normal dose every 12 hours
Half of the normal dose every 18-24 hours
In haemodialysis patients, the treatment schedule depends on the dialysis conditions.
Guidelines for adult dosage Reconstitution table for intramuscular injection
Content per vial
Amount of diluent to be added
Approximate concentration
1 g 2.5 mL 330 mg / mL
Reconstitution table for intravenous injection
Content per vial
Minimum amount of diluent to be added
Approximate concentration
1 g 4 mL 220 mg / mL
Paediatric population: Infections caused by sensitive microorganisms A dose of 25 – 50 mg / kg body weight divided into two to four equal doses per day is recommended (one dose every 6, 8 or 12 hours). Infections caused by moderately sensitive microorganisms A dose of up to 100 mg / kg body weight divided in three or four equal doses is recommended (one dose every 6 or 8 hours).
The following information is intended for healthcare professionals only:
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them.
You must stop taking the medicine and speak to your doctor straight away if you notice any of these symptoms: Uncommon: may affect up to 1 in 100 people
Reporting of side effects If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via: Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
5. How to store Cefazolin Keep this medicine out of the sight and reach of children. Do not use Cefazolin after the expiry date which is stated on the vial and carton after EXP. The expiry date refers to the last day of that month. Store below 30°C. Keep the vials in the outer carton in order to protect from light. After reconstitution/dilution Chemical and physical stability has been demonstrated for 12 hours at 25°C and for up to 24 hours at 2 – 8°C. From a microbiological point of view, unless the method of opening/ reconstitution/dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than the times stated above for the chemical and physical in-use stability. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6. Contents of the pack and other information What Cefazolin contains
Marketing Authorization Holder and Manufacturer Marketing Authorisation Holder: Noridem Enterprises Ltd., Evagorou & Makariou, Mitsi Building 3, Office 115, 1065 Nicosia, Cyprus. Manufacturer responsible for batch release: DEMO S.A. PHARMACEUTICAL INDUSTRY, 21 st^ km National Road Athens-Lamia, 14568 Krioneri, Attiki, Greece, T: +30 210 8161802, F: +30 2108161587. This medicinal product is authorised in the Member States of the EEA under the following names:
United Kingdom: Cefazolin 1 g Powder for solution for injection/infusion Cefazolin 2 g Powder for solution for injection/infusion Cyprus: Cefazolin/Noridem 1 g Κόνις για ενέσιμο διάλυμα/διάλυμα προς έγχυση Cefazolin/ Noridem 2 g Κόνις για ενέσιμο διάλυμα/ διάλυμα προς έγχυση Germany: Cefazolin Noridem 1 g Pulver zur Herstellung einer Injektions-/ Infusionslösung Cefazolin Noridem 2 g Pulver zur Herstellung einer Injektions-/ Infusionslösung France: CEFAZOLINE NORIDEM 1 g poudre pour solution injectable/pour perfusion CEFAZOLINE NORIDEM 2 g poudre pour solution injectable/pour perfusion Belgium: Cefazoline Noridem 1 g poudre pour solution injectable/pour perfusion - poeder voor oplossing voor injectie/infusie - Pulver zur Herstellung einer Injektions-/ Infusionslösung Cefazoline Noridem 2 g poudre pour solution injectable/pour perfusion - poeder voor oplossing voor injectie/ infusie - Pulver zur Herstellung einer Injektions-/ Infusionslösung Poland: Cefazolin Noridem Slovakia: Cefazolin Noridem 1 g prášok na injekčný/infúzny roztok Cefazolin Noridem 2 g prášok na injekčný /infúzny roztok Czech Republic: Cefazolin Noridem
This leaflet was last revised in 12/2018.
Prematures and infants below the age of 1 month Since safety of use in prematures and infants below the age of one month has not been determined, the use of Cefazolin in these patients is not recommended. Guidelines for paediatric dosage Intravenous injection 1 g vial: The content of 1 vial (1000 mg cefazolin) is dissolved in 4 mL of a compatible solvent (i.e. concentration approx. 220 mg / mL). The respective volume of this solution to be used is indicated in table 1 in addition to the dose in mg. 2 g vial: The content of 1 vial (2000 mg cefazolin) is dissolved in 10 mL of a compatible solvent (i.e. concentration approx. 180 mg / mL). The respective volume of this solution to be used is indicated in table 2 in addition to the dose in mg. Intravenous administration of lidocaine solutions must be strictly avoided.
Table 1: Appropriate volumes for intravenous and intramuscular injection for paediatric patients for Cefazolin 1 g Powder for solution for injection/infusion
Body weight Strength 5 kg 10 kg 15 kg 20 kg 25 kg
Divided dose every 12 hours at 25 mg / kg body weight / day
1-g vial
63 mg; 125 mg; 188 mg; 250 mg; 313 mg;
0.29 mL 0.57 mL 0.85 mL 1.14 mL 1.42 mL
Divided dose every 8 hours at 25 mg / kg body weight / day
1-g vial
42 mg; 85 mg; 125 mg; 167 mg; 208 mg;
0.19 mL 0.439mL 0.57 mL 0.76 mL 0.94 mL
Divided dose every 6 hours at 25 mg / kg body weight / day
1-g vial
31 mg; 62 mg; 94 mg; 125 mg; 156 mg;
0.14 mL 0.28 mL 0.43 mL 0.57 mL 0.71 mL
Divided dose every 12 hours at 50 mg / kg body weight / day
1-g vial
125 mg 250 mg; 375 mg; 500 mg; 625 mg;
0.57 mL 1.14 mL 1.7 mL 2.27mL* 2.84mL*
Divided dose every 8 hours at 50 mg / kg body weight/ day
1-g vial
83 mg; 166 mg; 250 mg; 333 mg; 417 mg;
mL 0.75 mL^ 1.14 mL^ 1.51 mL^ 1.89 mL
Divided dose every 6 hours at 50 mg / kg body weight/ day
1-g vial
63 mg; 125 mg; 188 mg; 250 mg; 313 mg;
0.29 mL 0.57 mL 0.85 mL 1.14 mL 1.42 mL
Divided dose every 8 hours at 100 mg / kg body weight/ day
1-g vial
167 mg; 333 mg; 500 mg; 667 mg; 833 mg;
0.76 mL 1.51 mL 2.27mL* 3.03mL* 3.79mL*
Divided dose every 6 hours at 100 mg / kg body weight/ day
1-g vial
125 mg 250 mg; 375 mg; 500 mg; 625 mg;
0.57 mL 1.14 mL 1.7 mL 2.27mL* 2.84mL*
Table 2: Appropriate volumes for intravenous injection for paediatric patients for Cefazolin 2 g Powder for solution for injection/infusion
Body weight Strength 5 kg 10 kg 15 kg 20 kg 25 kg
Divided dose every 12 hours at 25 mg / kg body weight/ day
2-g vial
63 mg; 125 mg; 188 mg; 250 mg; 313 mg;
0.35 mL 0.69 mL 1.04 mL 1.39 mL 1.74 mL
Divided dose every 8 hours at 25 mg / kg body weight/ day
2-g vial
42 mg; 85 mg; 125 mg; 167 mg; 208 mg;
0.23 mL 0.47mL 0.69 mL 0.93 mL 1.15 mL
Divided dose every 6 hours at 25 mg / kg body weight/ day
2-g vial
31 mg; 62 mg; 94 mg; 125 mg; 156 mg;
0.17 mL 0.34 mL 0.52 mL 0.69 mL 0.87 mL
Divided dose every 12 hours at 50 mg / kg body weight / day
2-g vial
125 mg 250 mg; 375 mg; 500 mg; 625 mg;
0.69 mL 1.39 mL 2.08 mL 2.78 mL 3.47 mL
Divided dose every 8 hours at 50 mg / kg body weight/ day
2-g vial
83 mg; 166 mg; 250 mg; 333 mg; 417 mg;
0.46 mL 0.92 mL 1.39 mL 1.85 mL 2.32 mL
Divided dose every 6 hours at 50 mg / kg body weight/ day
2-g vial
63 mg; 125 mg; 188 mg; 250 mg; 313 mg;
0.35 mL 0.69 mL 1.04 mL 1.39 mL 1.74 mL
Divided dose every 8 hours at 100 mg / kg body weight/ day
2-g vial
167 mg; 333 mg; 500 mg; 667 mg; 833 mg;
0.93 mL 1.85 mL 2.78 mL 3.7 mL 4.63 mL
Divided dose every 6 hours at 100 mg / kg body weight/ day
2-g vial
125 mg 250 mg; 375 mg; 500 mg; 625 mg;
0.69 mL 1.39 mL 2.08 mL 2.78 mL 3.47mL*
For volumes inferior of 1 mL, please use a 0.5 mL syringe for better accuracy of dosing. Intramuscular injection The content of 1 vial (1000 mg cefazolin) is dissolved in 4 mL of a compatible solvent (i.e. concentration approx. 220 mg / mL) and appropriate volume (as indicated in table 1) is withdrawn from the reconstituted solution and administered by intramuscular injection. For administration in children younger than 30 months of age, cefazolin should not be dissolved in lidocaine solution. Intravenous infusion The dosage can be given as intravenous infusion, using the reconstituted and further diluted solution (10 mg / mL) described in subsection “ Intravenous infusion ” of the Guidelines for adult dosage. Paediatric patients with renal impairment Children with renal impairment (like adults) may need a lower dose to avoid overlapping. This lower dose may be guided by determining blood levels. If not possible, the dosage may be determined based on creatinine clearance, according to the following guidelines. In children with moderate impairment (creatinine clearance 40 – 20 mL / min), 25 % of the normal daily dose, divided into doses every 12 hours are sufficient. In children with severe impairment (creatinine 20 – 5 mL / min) will be 10 % of normal daily dose, given every 24 hours are sufficient. All these guidelines are valid after an initial starting dose. Elderly patients: In elderly patients with normal renal function no dosage adjustment is necessary. Method of administration Cefazolin 1 g may be administered as a deep IM injection or by slow intravenous injection or intravenous infusion after dilution. Cefazolin 2 g may be administered by slow intravenous injection or intravenous infusion after dilution. Single doses exceeding 1 g should be given as intravenous infusion. The volume and type of diluent to be used for the reconstitution is dependent upon the method of administration. For instructions on the reconstitution of the medicinal product before administration, please see section Preparation and handling. If lidocaine is used as a solvent, the resulting solution should never be administered intravenously. Τhe information in the Summary of Product Characteristics of lidocaine should be considered. Duration of treatment The duration of the treatment depends on the severity of the infection as well as on the clinical and bacteriological progress. Disposal Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Overdose Symptoms of an overdose are headache, vertigo, paraesthesia, central nervous disorders such as agitation, myoclonia and convulsions. In case of poisoning, elimination accelerating measures are indicated. A specific antidote does not exist. Cefazolin can be haemodialysed.